Pugh’s responsibilities at Minneapolis-based Endogenex include expanding the company’s clinical initiatives evaluating its novel ReCET procedure. ReCET a novel, endoscopic, outpatient procedure, targets the underlying cellular abnormalities in the duodenum. These abnormalities contribute to the development and progression of type 2 diabetes.
According to Pugh’s LinkedIn page, the former Medtronic executive took over the corner office at Endogenex in December 2022.
Get the full story at our sister site, Drug Delivery Business News.